Movement Disorders

CLINICAL PRACTICE

Milestones in Tremor Research: 10 Years Later

Roberto Erro, MD, PhD,[1,*] [ID] Alfonso Fasano, MD, PhD,[2,3,4] [ID] Paolo Barone, MD, PhD,[1] and Kailash P. Bhatia, MD, FRCP[5] [ID]

Abstract: Major progress has occurred during the last decade in the field of tremor. From the clinical standpoint, a new classification has completely revised the nosology of tremor syndromes and has re-conceptualized essential tremor as a syndrome rather than a single disease entity, fueling an ongoing enlightened debate. Significant advances have been obtained in terms of instrumental measurement of tremor, remarking on the possibility of developing novel treatment strategies based on tremor characteristics, namely tremor-phase. Moreover, a better understanding of the pathophysiological mechanisms has further led to the suggestion of refining the classification of tremor syndromes according to their driving underpinnings. Finally, surgical options such as deep brain stimulation and focused ultrasound thalamotomy are now part of the therapeutic portfolio for tremor, but several oral drugs, including long-chain alcohols, T-channel blockers, allosteric modulators of potassium channels, and of GABA-A receptors, are currently being tested and hold promise. This review will discuss the key milestones in tremor research of the last 10 years, with a focus on the most common tremor syndromes, namely essential tremor, dystonic tremor, and Parkinsonian tremor.

At the time of writing, 10 years has passed since the article "Milestones in Tremor Research" by Rodger Elbe and Gunther Deuschl was published in *Movement Disorders*.[1] Based on a review of the previous 25 years, they highlighted the advances in tremor research and eventually concluded that it was "time to refine the classification and diagnostic criteria for various tremor disorders, particularly Essential Tremor (ET) and dystonic tremor (DT)".[1] This paper will serve as a starting point for the current work, in which we discuss the key advances of the last decade in terms of clinical concepts, tremor measurement, pathophysiology, and treatment approaches with a focus on the most common tremor syndromes, namely ET, DT, and Parkinson's disease (PD) related tremor. Conversely, this review will not go into etiological considerations, owing to the lack of consistent findings especially with regard to ET. The interested readership is referred elsewhere for consideration of the diverse etiologies, including genetics, that might sustain the syndrome of ET[2–4] as well as its heterogeneous post–mortem findings.[5–8]

Clinical Concepts

In 2018, the Tremor Task Force of the International Parkinson's and Movement Disorders Society (IPMDS) published the new tremor classification,[9] this probably being the most notable advance of the last decade. Mirroring the recent changes in the dystonia field, the main structure of the classification is based on two axes: clinical features (axis I) and etiology (axis II). The inspiring aim of the new classification is to facilitate deeper and detailed phenotyping of patients with tremor, given the failure of having identified robust pathophysiologic and etiologic correlates of any tremor syndromes, particularly of ET. In fact, decades of research on ET with its loosely defined boundaries have led to a lack of

[1]Department of Medicine, Surgery and Dentistry "Scuola Medica Salernitana", Neuroscience Section, University of Salerno, Baronissi, Italy; [2]Edmond J. Safra Program in Parkinson's Disease, Morton and Gloria Shulman Movement Disorders Clinic, Toronto Western Hospital, UHN, Toronto, Ontario, Canada; [3]Division of Neurology, University of Toronto, Toronto, Ontario, Canada; [4]Krembil Brain Institute, Toronto, Ontario, Canada; [5]Department of Clinical and Movement Neurosciences, University College London, London, United Kingdom

*Correspondence to: Dr. Roberto Erro, Department of Medicine, Surgery and Dentistry "Scuola Medica Salernitana", Neuroscience Section, University of Salerno, Via Allende, Baronissi, Salerno, Italy; E-mail: rerro@unisa.it

consensus about its epidemiology, defining clinical features and prognosis, neurophysiologic markers, and pathology.[10] Therefore, the argument has been put forward that "ET may have more than one etiology and vice-versa an etiology of ET could conceivably produce more than one clinical syndrome".[9] Accordingly, ET has been re-conceptualized as a clinical syndrome (axis I), rather than a single disease entity, consisting of an isolated bi-brachial action tremor of at least 3-year duration.[9] The 3-year time frame is admittedly arbitrary, and the entity of "indeterminate tremor" was coined for those seemingly ET patients with a shorter disease duration.

Furthermore, the construct of "ET-plus" was introduced for those patients fulfilling the criteria of ET, but also having either a rest tremor or additional "soft signs" that do not suffice to make an alternative diagnosis.[9] Reclassification of formerly diagnosed ET patients according to the new criteria has evidenced that ET in absence of soft signs would be less common than ET-plus.[11]

The construct of ET-plus represents another notable departure from the former tremor classification and owes to the lack of consensus among the panel of experts on which of these additional (soft) signs were acceptable within the definition of ET.[4] The most prominent criticism raised by some researchers against the construct of ET-plus stands in the lack of pathological differences between ET and ET-plus.[12] However, this criticism misinterprets that: (1) for neither tremor syndrome is there a generally accepted underlying pathology; and (2) that both ET and ET-plus are currently viewed as syndromes rather than single diseases.[13] Nonetheless, the construct of ET-plus has generated an enlightened debate about its validity,[12,14] with some researchers proposing that it could represent a later stage of ET based on the evidence that its defining characteristics vary as a function of disease duration.[15] It should be noted, however, that the transition between syndromic allocations (ie, from ET to ET-plus) can occur in the other direction (ie, from ET-plus to ET because of the resolution of the soft signs).[16] This example highlights one of the novelties of the current classification, that is, the possibility that one syndrome might "evolve" over time into another. Tracking transitions across different tremor syndromes will eventually clarify the controversial relationship between them, for example between ET and ET-plus or between ET and PD,[17] which is the reason why the idea of diseases with "antecedent ET" are described in the new classification.[9]

Importantly, some tremor syndromes that were loosely considered within the ET spectrum, including isolated head/voice tremor, task-specific tremors and orthostatic tremor, have been now conceptualized as different and discreet entities,[9] owing to accumulating evidence pointing to different pathophysiology.[18–20]

As discussed in more detail in the corresponding section, one possible caveat of the current classification is the lack of mention of pathophysiological mechanisms sustaining a particular syndrome. Using as an extreme example the recently described rare entity of "myogenic tremor",[21] the ET label might appear far-fetched, given that the pacemaker has been construed to be located at the level of the myofilaments, although neurophysiologic studies have suggested tremor amplification by an additional central loop modulating the clinical phenomenology.[22] Likewise, the border between ET and enhanced physiological tremor with a central component can be blurred and clinical differentiation between phenomenologically similar syndromes difficult in the absence of pathophysiological markers. Notwithstanding, the strict operational clinical criteria of the new classification will likely provide a rigorous framework for future translational research.

Tremor Measurement

Transducers have been used in the study of tremor for more than 100 years, but the large infusion of smartphones, tablets, and smartwatches has fostered the development of specialized software especially in the last decade, which by using on-board sensors, provide very precise linear measures of tremor as opposed to imprecise non-linear measures obtained by clinical ratings.[23] However, it should be noted that these recording and analysis procedures have not been strictly defined, so that the best protocol for tremor assessment has not yet been determined.[23] A number of factors including anatomic placement of the transducer, selection of motor task versus recording during spontaneous unconstrained activities, duration of sampling, and methods of spectral analysis, will influence tremor measurements.[23] Probably the hardest challenge to face relates to an inherent feature of tremor, namely within-subject fluctuations. Tremor changes because of disease progression or treatment cannot be captured until they exceed this natural variability. This likely explains the failure in detecting tremor progression using sensor-based measures rather than what would be obtained by clinical ratings alone.[24] Nonetheless, detailed characterization of tremor features by means of sensors may be helpful in the differential diagnosis between tremor syndromes,[25,26] to predict therapeutic outcomes,[27] and to adapt deep-brain stimulation (DBS) paradigms to individual tremor physiology.[28,29] It is, therefore, expected that transducers will be increasingly used in both clinical and research settings, also because they enable more frequent and/or longer tremor assessments, and they can be used almost anywhere without clinician raters and/or might be exploited to substantiate clinical ratings.[23]

The advances in the instrumental measurement of tremor reflect on the possibility of developing novel treatment strategies based on tremor characteristics, which can be sensitively measured only by means of sensors, which is why they are discussed in this section. For example, the detailed exploration of tremor characteristics with transducers, namely tremor phase, might allow phase-locked non-invasive stimulation as a new tool for treatment. Therefore, both in-phase and out-of-phase electrical muscle stimulation paradigms with pulse intensity over the motor threshold (ie, able to induce a muscle contraction) have been used with promising results.[30,31] The rationale is either to increase impedance at the tremulous joint or to generate counteracting forces in antagonist muscles that are opposite to those that generate tremor. Similarly, low-level, afferent electrical stimulation tuned to the tremor frequency has been also shown to reduce tremor.[32,33] Finally, a recent work has developed a strategy to compute the instantaneous phase of tremor in ET and applied a phase-locked cerebellar transcranial alternating current stimulation (tACS), further demonstrating that tremor amplitude

reduction was attributable to a disruption of the cascade of coherent activities in the downstream loop.[34]

Pathophysiology

One aspect that has been overlooked by the current classification of tremor, arguably because is out of its scope, is related to the pathophysiology. This let some authors to propose a pathophysiology-guided axis III.[35] In fact, different pathophysiological processes sustaining a similar syndrome are likely related to diverse etiologies. On the other hand, in a single disease multiple tremor types might be present as result of different pathophysiological processes. Both examples highlight how a pathophysiology-guided axis III might fill the gap between clinical aspects (axis I) and etiology (axis II). This is particularly relevant to the relationship between dystonia and both the ET-like tremors that some patients might present (the so-called "tremor associated with dystonia" [TAWD]) as well as ET in general. Likewise, such pathophysiology-guided axis might be useful in understanding the biological underpinnings of rarer forms of tremor, including task/position-specific tremor and isolated head/voice tremor.[18,19]

Expanding on, yet somehow diverging from the "olivary model" of ET,[36] it is now accepted that the key system involved in the pathophysiology of many tremors is the cerebello-thalamo-cortical (CTC) circuit, with other inter-connected areas including the basal ganglia,[37] the supplemental motor area and other cortical areas,[38–40] and the brainstem,[20] also being affected and potentially explaining the clinical differences between tremor syndromes. Notably, evidence from imaging and well as electroencephalographic/magnetoencephalographic studies have revealed a dynamic entrainment of multiple nodes of this network,[41–44] which would lead to a rhythmic modulation of muscle activity becoming apparent as tremor. However, it remains unclear where the oscillations primarily originate within the CTC network with different, alternative hypotheses being proposed.

A body of work suggested an increased cerebellar drive in ET (cerebellar oscillator hypothesis).[39,45] This might be sustained by synaptic pruning deficits of climbing fiber to Purkinje cell synapses,[45] which retrieves the inferior olive as a major spot of tremor generation.[36] Moreover, alternative evidence has suggested a key mechanism in the disconnection of cerebellar output pathways (cerebellar decoupling hypothesis).[40,46] Notably, each of these abnormalities might not be present in all ET patients as suggested by studies comparing early- and late-onset cases,[47] sporadic and familial patients,[48] or by indirect clinical evidence demonstrating different tremor characteristics across different activating conditions in ET,[49] which would point to different pathophysiological mechanisms.[50] Of note, most of these studies have been carried out before the new tremor classification was published and it is, therefore, unknown whether these concepts apply to both ET and ET-plus.

Interestingly, the spectrum of tremor types occurring in dystonia syndromes might be also sustained by different mechanisms. Although some authors suggested a cerebellar involvement in both DT and TAWD,[37,51] others supported a prominent role of basal ganglia in DT[52] or suggested differential pathophysiology between the two types of tremor, with DT being closer to non-tremulous dystonia and TAWD to ET.[53] Furthermore, evidence arising from pallidal single-neuron recordings in cervical dystonia would support the notion that phenomenologically different tremors (ie, sinusoidal vs. jerky tremor) might have different pathophysiology,[54] arguably independent from tremor distribution. Therefore, sinusoidal tremor (ie, "ET-like") would be driven by cerebellar alterations whereas jerky tremor by pallidal alterations.[54]

Somewhat similarly, it has been shown that different types of tremor occurring in PD might relate to different pathophysiologic

FIG. 1. Suggested pathophysiological mechanisms sustaining essential tremor, dystonic tremors, and parkinsonian tremors (whitened boxes indicate a possible but minor contribution; redrawn from van der Stouwe et al).[35] ET, essential tremor; TAWD, tremor associated with dystonia; DT, dystonic tremor.

mechanisms. Therefore, some PD patients exhibit a pure postural tremor, which is not re-emergent, has a higher frequency than the rest component, and does not respond to levodopa, all features contrasting with the re-emergent tremor that is highly correlated with resting tremor.[55] Interestingly, such dopamine-resistant tremor depends on an increased tremor-related activity in the cerebellum, whereas patients with dopamine-responsive tremor have increased thalamic ventralis intermediate nucleus (VIM)-cortical activity.[56,57] These concepts have been summarized as the "dimmer-switch" theory of PD tremor formulated by Rick Helmich and colleagues.[58]

In summary, significant advances in the last decade have highlighted that different pathophysiologic mechanisms, at least in terms of involved circuitry, might occur across and within different tremor syndromes (Fig. 1). It should be noted however, that the demonstration of specific neuro-imaging and/or electrophysiological changes are permissible within axis I of the new tremor classification, according to which information from four main domains (ie, historical features, tremor characteristics, associated signs, and, indeed, findings from additional laboratory tests) should be gathered.[9] This emphasizes the concept that the definition of a clinical syndrome by axis I should not be made solely on features that can be collected with the naked eye. Nonetheless, the current classification does not require any additional testing for the formal definition of the proposed tremor syndromes,[9] not even the loading test for the distinction between mechanical-reflex and central neurogenic tremors. On the contrary, some easy-to-collect neurophysiological measures (ie, the tremor stability index, which is a proxy of variability in the tremor period or frequency) have been suggested to accurately differentiate between different tremor syndromes, namely ET and PD-related tremor.[59]

Hence, the identification of the pathophysiological underpinnings sustaining the clinical variability within and between different tremor syndromes and/or the recognition of physiological markers reflecting this variability might theoretically have therapeutic implications, as continued below.

Treatment

There have not been significant advances in the commercialized pharmacological treatment of tremor, as appraised in the 2019 IPMDS evidence-based review.[60] Nonetheless, it is worth noting that, based on positive preclinical evidence, long-chain alcohols including 1-octanol and its metabolite octanoic acid (OA) have been recently tested in ET. Despite some evidence of efficacy, the actual viability of 1-octanol therapy is limited by its pharmacological properties that require large volumes to be orally administered.[61] Conversely, the first trial using OA demonstrated excellent safety as well as efficacy in secondary, but not primary, outcome measures of tremor amplitude.[61] It is expected that OA will be tested in additional phase-2 trials, perhaps targeting different tremor syndromes. More importantly, for the first time in history a number of companies have anti-tremor drugs in the pipeline. These are T-channel blocking agents (CX-8998, PRAX-944), an allosteric modulator of small conductance calcium-activated potassium channels (CAD-1883), and allosteric modulators of GABA-A receptors (brexanolone, SAGE 217 and 234).[62]

Surgical treatment of tremor has become standard of care in many countries and is now an integral part of the anti-tremor portfolio. New technologies are being implemented for VIM DBS in particular. These include the use of directional stimulation[63] and/or short pulse width,[64] technologies able to expand the therapeutic window of stimulation, also making safer the use of bilateral DBS in terms of balance and other ataxia side effects of stimulation.[65] Adaptive DBS (aDBS) of VIM is only investigational at the moment but preliminary reports on two subjects also implanted with electrocorticography strips over the hand portion of M1 to close the loop, have provided initial evidence of its feasibility.[66,67] Building on previous pathophysiological studies,[29,43] future aDBS approaches will use thalamic recordings to close the loop thereby stimulating the oscillatory activity of these neurons only during certain phases. The possibility of thalamic recording in tremor patients is already feasible with recently commercialized DBS devices.[68] How these new technologies will reduce the still unclear phenomenon of DBS "habituation" (or "tolerance") is uncertain although aDBS seems to be the most promising approach in this regard.[69] Nevertheless, long-term prospective studies of patients treated with VIM DBS are now available and overall indicate a reasonably sustained benefit in most ET patients.[70]

MRI-guided focused ultrasound (MRgFUS) thalamotomy has been the most interesting advance in the surgical treatment of tremor during the past 10 years. MRgFUS uses over a thousand transducers to focus ultrasound beams on a precise brain location, therefore, creating a coagulative lesion, a thalamotomy in the case of tremor.[71] This therapy is now approved for ET in many countries, as a number of prospective studies—including a randomized sham-controlled blind trial—have been conducted.[72] MRgFUS thalamotomy has been conducted also in other tremor syndromes, including DT and PD-related tremor.[73] Tremor outcome in the short term is comparable to VIM DBS although a decay of benefit, requiring repeated treatment, has been consistently reported.[74] Safety profile is satisfactory and the absence of craniectomy and general anesthesia makes elderly patients suitable candidates.[75] More recently, staged bilateral MRgFUS thalamotomy has been shown to be both effective and safe in ET patients.[76]

Moreover, the advances in neuroimaging have allowed a more precise targeting for all surgical therapies of tremor, particularly through the direct visualization of the dento–rubro–thalamic tract.[77] Imaging has also allowed the understanding of the "sweet spots" of VIM DBS[78] as well as MRgFUS.[79,80]

Last, a novel venue of research has recently explored the possibility of suppressing tremor by means of non-invasive stimulation approaches. Therefore, expanding on the results of Schreglmann and colleagues[34] who successfully applied a phase-locked cerebellar tACS in ET, Nieuwhof et al[81] adopted an identical approach to dystonic tremors demonstrating that phase-locked cerebellar tACS modulated tremor amplitude solely in patients with sinusoidal tremor, but not in patients with jerky (irregular) tremor. This reflects on the concept that the cerebellum plays a causal role in the generation of sinusoidal dystonic tremor syndromes (Fig. 1) and further opens the question of whether differential targets of DBS (ie, cerebellar relay vs pallidal relay thalamic nuclei) should be tailored according to the specific circuitry involved in tremor generation.[49,82]

Conclusions

The past decade has generated major advances in our knowledge about tremor, paving the way toward the unmet needs in the field, which are the discovery of the different etiologies that cause tremor and the development of pathophysiology-driven treatments. The next steps on the roadmap to attain these objectives will keep us busy for the next decade.

Acknowledgments

Author Roles

(1) Conception and design of the study, or acquisition of data, or analysis and interpretation of data; (2) Drafting the article or revising it critically for important intellectual content; (3) Final approval of the version to be submitted.

R.E.: 1, 2, 3
A.F.: 2, 3
P.B.:2,3
K.P.B.: 2, 3

Disclosures

Ethical Compliance Statement: The authors confirm that the approval of an institutional review board and patient consent was not required for this work. We confirm that we have read the Journal's position on issues involved in ethical publication and affirm that this work is consistent with those guidelines.

Funding Sources and Conflicts of Interest: No specific funding was received for this work. The authors declare that there are no conflicts of interest relevant to this work.

Financial Disclosures for the Previous 12 Months: R.E. receives royalties from publication of Case Studies in Movement Disorders—Common and Uncommon Presentations (Cambridge University Press, 2017) and of Paroxysmal Movement Disorders (Springer, 2020). He has received consultancies from Sanofi and honoraria for speaking from the International Parkinson's Disease and Movement Disorders Society.

P.B. received consultancies as a member of the advisory board for Zambon, Lundbeck, UCB, Chiesi, Abbvie, and Acorda.

K.P.B. has received grant support from EU Horizon 2020. He receives royalties from publication of the Oxford Specialist Handbook Parkinson's Disease and Other Movement Disorders (Oxford University Press, 2008), of Marsden's Book of Movement Disorders (Oxford University Press, 2012), and of Case Studies in Movement Disorders—Common and uncommon presentations (Cambridge University Press, 2017). He has received honoraria/

personal compensation for participating as consultant/scientific board member from Ipsen, Allergan, and honoraria for speaking at meetings from Allergan, Ipsen, and the International Parkinson's Disease and Movement Disorders Society.

A.F. has received consultancies from Apple, Abbvie, Abbott, Medtronic, Boston Scientific, Sunovion, Chiesi farmaceutici, UCB, Ipsen, and Rune Labs; he serves on the Advisory Boards of Abbvie, Boston Scientific, Ceregate, Gondola, Inbrain, and Ipsen; he has received honoraria from American Academy of Neurology, Abbott, Abbvie, Medtronic, Boston Scientific, Sunovion, Chiesi farmaceutici, UCB, Ipsen, Paladin Lab, and Movement Disorders Society; he has received royalties from Springer; he has received grants from the University of Toronto, Abbvie, Medtronic, Boston Scientific, MSA Coalition, and McLaughlin Centre. ■

References

1. Elble R, Deuschl G. Milestones in tremor research. *Mov Disord* 2011 May;26(6):1096–1105.
2. Tio M, Tan EK. Genetics of essential tremor. *Parkinsonism Relat Disord* 2016;22(Suppl 1):S176–S178.
3. Sun QY, Xu Q, Tian Y, Hu ZM, Qin LX, Yang JX, et al. Expansion of GGC repeat in the human specific NOTCH2NLC gene is associated with essential tremor. *Brain* 2020;143(1):222–233.
4. Fasano A, Lang AE, Espay AJ. What is "essential" about essential tremor? *A diagnostic placeholder movement disorders* 2018;33(1):58–61.
5. Louis ED, Honig LS, Vonsattel JP, Maraganore DM, Borden S, Moskowitz CB. Essential tremor associated with focal nonnigral Lewy bodies: A clinicopathologic study. *Arch Neurol* 2005;62(6):1004–1007.
6. Louis ED, Kerridge CA, Chatterjee D, Martuscello RT, Diaz DT, Koeppen AH, et al. Contextualizing the pathology in the essential tremor cerebellar cortex: a patholog-omics approach. *Acta Neuropathol* 2019;138(5):859–876.
7. Rajput AH, Robinson CA, Rajput A. Purkinje cell loss is neither pathological basis nor characteristic of essential tremor. *Parkinsonism Relat Disord* 2013;19(4):490–491.
8. Louis ED, Faust PL, Vonsattel JP, Honig LS, Rajput A, Robinson CA, et al. Neuropathological changes in essential tremor: 33 cases compared with 21 controls. *Brain* 2007;130(Pt 12):3297–3307.
9. Bhatia KP, Bain P, Bajaj N, et al. Consensus statement on the classification of tremors. From the task force on tremor of the International Parkinson and Movement Disorder Society. *Mov Disord* 2018 Jan;33(1):75–87.
10. Espay AJ, Lang AE, Erro R, Merola A, Fasano A, Berardelli A, Bhatia KP. Essential pitfalls in "essential" tremor. *Mov Disord* 2017 Mar;32(3):325–331.
11. Rajalingam R, Breen DP, Lang AE, Fasano A. Essential tremor plus is more common than essential tremor: Insights from the reclassification of a cohort of patients with lower limb tremor. *Parkinsonism Relat Disord* 2018 Nov;56:109–110.
12. Gionco JT, Hartstone WG, Martuscello RT, Kuo SH, Faust PL, Louis ED. Essential tremor versus "ET-plus": a detailed postmortem study of cerebellar pathology. *Cerebellum* 2021;20(6):904–912. https://doi.org/10.1007/s12311-021-01263-6.
13. Elble RJ. Do we belittle essential tremor by calling it a syndrome rather than a disease? No. *Front Neurol* 2020;30(11):586606.
14. Louis ED, Bares M, Benito-Leon J, et al. Essential tremor-plus: a controversial new concept. *Lancet Neurol* 2020 Mar;19(3):266–270.
15. Louis ED, Huey ED, Cosentino S. Features of "ET plus" correlate with age and tremor duration: "ET plus" may be a disease stage rather than a subtype of essential tremor. *Parkinsonism Relat Disord* 2021;1(91):42–47.
16. Iglesias-Hernandez D, Delgado N, McGurn M, Huey ED, Cosentino S, Louis ED. "ET plus": instability of the diagnosis during prospective longitudinal follow-up of essential tremor cases. *Front Neurol* 2021;12:2348.

17. Algarni M, Fasano A. The overlap between essential tremor and Parkinson disease. *Parkinsonism Relat Disord* 2018;46(Suppl 1):S101–S104.

18. Conte A, Ferrazzano G, Manzo N, et al. Somatosensory temporal discrimination in essential tremor and isolated head and voice tremors. *Mov Disord* 2015;30(6):822–827.

19. Latorre A, Rocchi L, Batla A, Berardelli A, Rothwell JC, Bhatia KP. The signature of primary writing tremor is dystonic. *Mov Disord* 2021; 36(7):1715–1720.

20. Schöberl F, Feil K, Xiong G, et al. Pathological ponto-cerebello-thalamo-cortical activations in primary orthostatic tremor during lying and stance. *Brain* 2017;140(1):83–97.

21. Schaefer J, Saak A, Bönnemann CG, Jackson S. Myogenic tremor – a novel tremor entity. *Curr Opin Neurol* 2021;34(5):706–713. https://doi.org/10.1097/WCO.0000000000000976.

22. Stavusis J, Lace B, Schäfer J, et al. Novel mutations in MYBPC1 are associated with myogenic tremor and mild myopathy. *Ann Neurol* 2019; 86(1):129–142.

23. Haubenberger D, Abbruzzese G, Bain PG, et al. Transducer-based evaluation of tremor. *Mov Disord* 2016;31(9):1327–1336.

24. Goetz CG, Stebbins GT, Wolff D, DeLeeuw W, Bronte-Stewart H, Elble R, et al. Testing objective measures of motor impairment in early Parkinson's disease: feasibility study of an at-home testing device. *Mov Disord* 2009;24:551–556.

25. Nisticò R, Fratto A, Vescio B, Arabia G, Sciacca G, Morelli M, et al. Tremor pattern differentiates drug-induced resting tremor from Parkinson disease. *Parkinsonism Relat Disord* 2016;25:100–103.

26. Su D, Zhang F, Liu Z, et al. Different effects of essential tremor and Parkinsonian tremor on multiscale dynamics of hand tremor. *Clin Neurophysiol* 2021;132(9):2282–2289.

27. Rüegge D, Mahendran S, Stieglitz LH, et al. Tremor analysis with wearable sensors correlates with outcome after thalamic deep brain stimulation. *Clin Park Relat Disord* 2020;5(3):100066.

28. Cernera S, Alcantara JD, Opri E, et al. Wearable sensor-driven responsive deep brain stimulation for essential tremor. *Brain Stimul* 2021;14(6): 1434–1443.

29. Cagnan H, Pedrosa D, Little S, et al. Stimulating at the right time: phase-specific deep brain stimulation. *Brain* 2017;140(1):132–145.

30. Jitkritsadakul O, Thanawattano C, Anan C, Bhidayasiri R. Tremor's glove: an innovative electrical muscle stimulation therapy for intractable tremor in Parkinson's disease: a randomized sham-controlled trial. *J Neurol Sci* 2017;381:331–340.

31. Widjaja F, Shee CY, Ang WT, Au WL, Poignet P. Sensing of pathological tremor using surface electromyography and accelerometer for real-time attenuation. *J Mech Med Biol* 2011;11:1347–1371.

32. Lin PT, Ross EK, Chidester P, Rosenbluth KH, Hamner SR, Wong SH, et al. Noninvasive neuromodulation in essential tremor demonstrates relief in a sham-controlled pilot trial. *Mov Disord* 2018;33:1182–1183.

33. Pahwa R, Dhall R, Ostrem J, Gwinn R, Lyons K, Ro S, et al. An acute randomized controlled trial of noninvasive peripheral nerve stimulation in essential tremor. *Neuromodulation* 2019;22:537–545.

34. Schreglmann SR, Wang D, Peach RL, Li J, Zhang X, Latorre A, et al. Non-invasive suppression of essential tremor via phase-locked disruption of its temporal coherence. *Nat Commun* 2021;12(1):363.

35. Madelein van der Stouwe AM, Nieuwhof F, Helmich RC. Tremor pathophysiology: lessons from neuroimaging. *Curr Opin Neurol* 2020; 33(4):474–481.

36. Louis ED, Lenka A. The olivary hypothesis of essential tremor: time to lay this model to rest? *Tremor Other Hyperkinet Mov (N Y)*. 2017;13(7):473.

37. DeSimone JC, Archer DB, Vaillancourt DE, Wagle SA. Network-level connectivity is a critical feature distinguishing dystonic tremor and essential tremor. *Brain* 2019;142:1644–1659.

38. Archer DB, Coombes SA, Chu WT, et al. A widespread visually-sensitive functional network relates to symptoms in essential tremor. *Brain* 2018;141:472–485.

39. Awad A, Blomstedt P, Westling G, Eriksson J. Deep brain stimulation in the caudal zona incerta modulates the sensorimotor cerebello-cerebral circuit in essential tremor. *Neuroimage* 2020;209:116511.

40. Tikoo S, Pietracupa S, Tommasin S, et al. Functional disconnection of the dentate nucleus in essential tremor. *J Neurol* 2020;267:1358–1367.

41. Nicoletti V, Cecchi P, Pesaresi I, Frosini D, Cosottini M, Ceravolo R. Cerebello-thalamo-cortical network is intrinsically altered in essential tremor: Evidence from a resting state functional MRI study. *Sci Rep* 2020;10(1):16661.

42. Raethjen J, Muthuraman M. Cause or compensation? Complex changes in cerebello-thalamo-cortical networks in pathological action tremor. *Brain* 2015;138:2808–2810.

43. He F, Sarrigiannis PG, Billings SA, et al. Nonlinear interactions in the thalamocortical loop in essential tremor: a model-based frequency domain analysis. *Neuroscience* 2016;2(324):377–389.

44. Muthuraman M, Raethjen J, Koirala N, et al. Cerebello-cortical network fingerprints differ between essential. *Parkinson's and mimicked tremors Brain* 2018;141(6):1770–1781.

45. Pan MK, Li YS, Wong SB, Ni C-L, Wang Y-M, Liu W-C, et al. Cerebellar oscillations driven by synaptic pruning deficits of cerebellar climbing fibers contribute to tremor pathophysiology. *Sci Transl Med* 2020;12:eaay1769.

46. Juttukonda MR, Franco G, Englot DJ, et al. White matter differences between essential tremor and Parkinson disease. *Neurology* 2019;92:e30–e39.

47. Muthuraman M, Deuschl G, Anwar AR, et al. Essential and aging-related tremor: differences of central control. *Movement Disord* 2015;30: 1673–1680.

48. Wong SB, Wang YM, Lin CC, et al. Cerebellar oscillations in familial and sporadic essential tremor. *Cerebellum* 2021. https://doi.org/10.1007/s12311-021-01309-9.

49. Schuhmayer N, Weber C, Kieler M, Voller B, Pirker W, Auff E, et al. Task-dependent variability of essential tremor. *Parkinsonism Relat Disord* 2017;41:79–85.

50. Zakaria R, Lenz FA, Hua S, Avin BH, Liu CC, Mari Z. Thalamic physiology of intentional essential tremor is more like cerebellar tremor than postural essential tremor. *Brain Res* 2013;5(1529):188–199.

51. Antelmi E, Di Stasio F, Rocchi L, et al. Impaired eye blink classical conditioning distinguishes dystonic patients with and without tremor. *Parkinsonism Relat Disord* 2016 Oct;31:23–27.

52. Battistella G, Simonyan K. Top-down alteration of functional connectivity within the sensorimotor network in focal dystonia. *Neurology* 2019; 92:e1843–e1851.

53. Panyakaew P, Cho HJ, Lee SW, Wu T, Hallett M. The pathophysiology of dystonic tremors and comparison with essential tremor. *J Neurosci* 2020;40(48):9317–9326.

54. Sedov A, Usova S, Semenova U, Gamaleya A, Tomskiy A, Beylergil SB, et al. Pallidal activity in cervical dystonia with and without head tremor. *Cerebellum* 2020;19:409–418.

55. Dirkx MF, Zach H, Bloem BR, Hallett M, Helmich RC. The nature of postural tremor in Parkinson disease. *Neurology* 2018;90:e1095–e1103.

56. Dirkx MF, Zach H, van Nuland A, Bloem BR, Toni I, Helmich RC. Cerebral differences between dopamine-resistant and dopamine-responsive Parkinson's tremor. *Brain* 2019;142:3144–3157.

57. Dirkx MF, den Ouden HE, Aarts E, et al. Dopamine controls Parkinson's tremor by inhibiting the cerebellar thalamus. *Brain* 2017;140: 721–734.

58. Helmich RC, Hallett M, Deuschl G, Toni I, Bloem BR. Cerebral causes and consequences of Parkinsonian resting tremor: a tale of two circuits? *Brain* 2012;135(Pt 11):3206–3226.

59. di Biase L, Brittain JS, Shah SA, et al. Tremor stability index: a new tool for differential diagnosis in tremor syndromes. *Brain* 2017;140(7):1977–1986.

60. Ferreira JJ, Mestre TA, Lyons KE, et al. MDS task force on tremor and the MDS evidence based medicine committee. MDS evidence-based review of treatments for essential tremor. *Mov Disord* 2019;34(7): 950–958.

61. Haubenberger D, Nahab FB, Voller B, Hallett M. Treatment of essential tremor with long-chain alcohols: still experimental or ready for prime time? *Tremor Other Hyperkinet Mov (N Y)* 2014;4:tre-04-211-4673-2.

62. Ondo WG. Current and emerging treatments of essential tremor. *Neurol Clin* 2020;38(2):309–323.

63. Rebelo P, Green AL, Aziz TZ, Kent A, Schafer D, Venkatesan L, Cheeran B. Thalamic directional deep brain stimulation for tremor: spend less, get more. *Brain Stimul* 2018;11(3):600–606.

64. Kroneberg D, Ewert S, Meyer AC, Kühn AA. Shorter pulse width reduces gait disturbances following deep brain stimulation for essential tremor. *J Neurol Neurosurg Psychiatry* 2019;90(9):1046–1050.

65. Mitchell KT, Larson P, Starr PA, et al. Benefits and risks of unilateral and bilateral ventral intermediate nucleus deep brain stimulation for

axial essential tremor symptoms. *Parkinsonism Relat Disord* 2019;60: 126–132.

66. Ferleger BI, Houston B, Thompson MC, et al. Fully implanted adaptive deep brain stimulation in freely moving essential tremor patients. *J Neural Eng* 2020;17(5):056026.

67. Herron JA, Thompson MC, Brown T, Chizeck HJ, Ojemann JG, Ko AL. Chronic electrocorticography for sensing movement intention and closed-loop deep brain stimulation with wearable sensors in an essential tremor patient. *J Neurosurg* 2017;127(3):580–587.

68. Goyal A, Goetz S, Stanslaski S, et al. The development of an implantable deep brain stimulation device with simultaneous chronic electrophysiological recording and stimulation in humans. *Biosens Bioelectron* 2021; 15(176):112888.

69. Fasano A, Helmich RC. Tremor habituation to deep brain stimulation: underlying mechanisms and solutions. *Mov Disord* 2019;34(12):1761–1773.

70. Cury RG, Fraix V, Castrioto A, et al. Thalamic deep brain stimulation for tremor in Parkinson disease, essential tremor, and dystonia. *Neurology* 2017;89(13):1416–1423.

71. Rohani M, Fasano A. Focused ultrasound for essential tremor: review of the evidence and discussion of current hurdles. *Tremor Other Hyperkinet Mov (N Y)* 2017;5(7):462.

72. Elias WJ, Lipsman N, Ondo WG, et al. A randomized trial of focused ultrasound thalamotomy for essential tremor. *N Engl J Med* 2016;375(8): 730–739.

73. Fasano A, Llinas M, Munhoz RP, Hlasny E, Kucharczyk W, Lozano AM. MRI-guided focused ultrasound thalamotomy in non-ET tremor syndromes. *Neurology* 2017;89(8):771–775.

74. Fasano A, De Vloo P, Llinas M, Hlasny E, Kucharczyk W, Hamani C, Lozano AM. Magnetic resonance imaging-guided focused ultrasound thalamotomy in Parkinson tremor: reoperation after benefit decay. *Mov Disord* 2018;33(5):848–849.

75. Paff M, Boutet A, Neudorfer C, et al. Magnetic resonance-guided focused ultrasound thalamotomy to treat essential tremor in nonagenarians. *Stereotact Funct Neurosurg* 2020;98(3):182–186. https://doi.org/10.1159/000506817.

76. Iorio-Morin C, Yamamoto K, Sarica C, et al. Bilateral focused ultrasound thalamotomy for essential tremor (BEST-FUS phase 2 trial). *Mov Disord* 2021;36(11):2653–2662.

77. Ranjan M, Elias GJB, Boutet A, et al. Tractography-based targeting of the ventral intermediate nucleus: accuracy and clinical utility in MRgFUS thalamotomy. *J Neurosurg* 2019;27:1–8.

78. Elias GJB, Boutet A, Joel SE, et al. Probabilistic mapping of deep brain stimulation: insights from 15 years of therapy. *Ann Neurol* 2021;89(3): 426–443.

79. Boutet A, Ranjan M, Zhong J, et al. Focused ultrasound thalamotomy location determines clinical benefits in patients with essential tremor. *Brain* 2018;141(12):3405–3414.

80. Kapadia AN, Elias GJB, Boutet A, et al. Multimodal MRI for MRgFUS in essential tremor: post-treatment radiological markers of clinical outcome. *J Neurol Neurosurg Psychiatry* 2020;91(9):921–927.

81. Nieuwhof F, Toni I, Buijink AWG, van Rootselaar AF, van de Warrenburg BPC, Helmich RC. Phase-locked transcranial electrical brain stimulation for tremor suppression in dystonic tremor syndromes. medRxiv 2021.11.03.21265869; doi: https://doi.org/10.1101/2021.11.03.21265869

82. Mongardi L, Rispoli V, Scerrati A, et al. Deep brain stimulation of the ventralis oralis anterior thalamic nucleus is effective for dystonic tremor. *Parkinsonism Relat Disord* 2020;81:8–11.